Condition 1: Functional dyspepsia. Condition 2: Helicobacter pylori. Functional dyspepsia Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: Esomeperazole Cap 40 mg BD + Amoxicillin Cap 500 mg 2*BD + Clarithromycin Tab 500 mg BD + Pyloshot Tab for 10 days. Intervention 2: Control group: Esomeperazole Cap
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients aged between 18 to 70 years old with dyspepsia presentation H. Pylori documentation by antral biopsy (Rapid Urease Test or Giemsa staining) or Urea Breath Test
Exclusion criteria
Exclusion criteria: Pregnancy or breast- feeding Women taking oral contraceptive pill (OCP) Significant underlying diseases such as cardiac, pulmonary, renal, liver, endocrine, central nervous system (CNS) diseases and cancers Previous history of gastric surgery Patients taking triple therapy for H. Pylori eradication History of taking proton pump inhibitor (PPI), histamine H2- receptor blocker (H2B) or antibiotic during previous two weeks Concomitant use of anticoagulant or corticosteroid Previous history of taking monoamine oxidase (MAO) inhibitors or tricyclic antidepressants (TCA)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter Pylori eradication rate. Timepoint: Six weeks after the end of therapy. Method of measurement: Stool Antigen Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of supplementation's side effects. Timepoint: After end of the therapy. Method of measurement: Patients' follow-up checklist.;Patient's compliance rate. Timepoint: After end of the therapy. Method of measurement: Patients' follow-up checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Mokhtare
Iran University of Medical Sciences
Outcome results
None listed